Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc.

RARE | NASDAQ
Chart Builder DCF Calculator
$16.05
+$1.40 (+9.56%)
Sep 22, 2026, 12:47 PM ET · Market open
Fiscal Year
Period Ending
FY 2025
Dec 30, 2025
FY 2024
Dec 30, 2024
FY 2023
Dec 30, 2023
FY 2022
Dec 30, 2022
FY 2021
Dec 30, 2021
FY 2020
Dec 30, 2020
Cash & Equivalents
434M 173.73M 213.58M 132.94M 307.58M 713.53M
Short-Term Investments
259M 436.3M 363.63M 614.82M 432.61M 488.01M
Long-Term Investments
59M 135M 199.9M 148.97M 293.86M 165.88M
Other Long-Term Assets
35M 62.68M 57.69M 48.34M 20.56M 8.81M
Receivables
159M 121.8M 73.39M 40.45M 44.43M 23.09M
Inventory
52M 45.01M 33.97M 26.77M 16.23M 13.05M
Other Current Assets
47M 40.29M 47.62M 68.93M 55.75M n/a
Total Current Assets
951M 817.12M 732.18M 883.9M 856.6M 1.3B
Property-Plant & Equipment
267M 265.93M 290.57M 259.73M 176.18M 114.04M
Goodwill & Intangibles
220M 222.72M 210.68M 204.51M 175.19M 175.52M
Total Long-Term Assets
581M 686.33M 758.83M 661.55M 665.79M 464.25M
Total Assets
1.53B 1.5B 1.49B 1.55B 1.52B 1.76B
Account Payables
31M 38.76M 42.11M 43.27M 17.14M 12.92M
Deferred Revenue
n/a n/a n/a 1.48M 7.61M 59.22M
Short-Term Debt
81M n/a n/a n/a n/a n/a
Other Current Liabilities
183M 87.47M 142.79M n/a n/a n/a
Total Current Liabilities
384M 344.15M 280.44M 261.21M 181.37M 189.61M
Long-Term Debt
1.17B n/a n/a n/a n/a n/a
Other Long-Term Liabilities
-4M 836.91M 874.53M 880.26M 352.79M 335.67M
Total Long-Term Liabilities
1.22B 897.01M 935.16M 931.74M 418.47M 415.57M
Total Liabilities
1.61B 1.24B 1.22B 1.19B 599.84M 605.18M
Total Debt
1.28B 40.34M 43.17M 31.59M 41.97M 48.23M
Book Value
-73M 262.3M 275.41M 352.49M 922.56M 1.15B
Book Value Per Share
-0.74 2.90 3.74 5.04 13.61 18.97
Common Stock
n/a 92K 82K 70K 69K 67K
Retained Earnings
-4.53B -3.96B -3.39B -2.78B -2.07B -1.62B
Comprehensive Income
1M -643K 647K -6.57M -1.4M 689K
Shareholders Equity
-80M 255.3M 275.41M 352.49M 922.56M 1.15B
Total Investments
318M 571.3M 563.53M 763.79M 726.47M 653.89M

© 2026 bestshares.com. All rights reserved.